Updated information on Pfizer recall of Chantix
Monday, July 19, 2021
Posted by: Natalia Gromov
Updated information on Pfizer recall of Chantix
Dear Colleagues,
On July 2, 2021, FDA announced that Pfizer would voluntarily recall nine lots of Chantix (varenicline) due to a nitrosamine impurity in the product that was above acceptable levels. The nitrosamine impurity may be associated with potential increased risk of cancer. FDA noted that there is no immediate risk to patients taking this medication and that the health benefits of stopping smoking outweigh the cancer risk from the nitrosamine impurity.
Yesterday, the voluntary recall has been expanded to 12 lots of Chantix. To stay updated on changes in the recall and for detailed information for health care providers and patients, please refer to the FDA’s website and announcement:
https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-nitrosamine-varenicline-chantix
Sincerely,
NAQC Staff |
|
|
|
Email to a Friend